---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):		May 6, 2010

HALOZYME THERAPEUTICS, INC.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	001-32335	88-0488686
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
11388 Sorrento Valley Road, San Diego, California		92121
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code:		858-794-8889

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2010, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2010. The press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 5.07 Submission of Matters to a Vote of Security Holders.

Our Annual Meeting of Stockholders was held on May 6, 2010. At the Annual Meeting, the total number of shares represented in person or by proxy was 75,620,210. Our stockholders voted on the following two proposals:

Proposal No. 1:

To elect three Class III directors to hold office for a three-year term and until their respective successors are elected and qualified. The voting results were as follows:

All three nominees were elected to the board of directors. We also have: (i) three Class I directors, Kathryn E. Falberg, Kenneth J. Kelley and Jonathan E. Lim, M.D., whose terms do not expire until our Annual Meeting of Stockholders in 2011 and (ii) two Class II directors, Randal J. Kirk and John S. Patton, Ph.D., whose terms do not expire until our Annual Meeting of Stockholders in 2012.

Proposal No. 2:

To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2010. The voting results were as follows:

The foregoing proposal was approved.

Item 9.01 Financial Statements and Exhibits.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HALOZYME THERAPEUTICS, INC.
May 7, 2010		By:		James E. Cartoni
				Name: James E. Cartoni
				Title: Secretary and Vice President, Legal

---

Exhibit Index

Exhibit No.		Description
99.1		Press release, dated May 7, 2010